Improvement situation on indexes of the zebrafish disease model of non-alcoholic fatty liver disease with FGF21 analogues.
10.3760/cma.j.cn501113-20230103-00002
- VernacularTitle:成纤维细胞生长因子21类似物对非酒精性脂肪性肝病斑马鱼模型疾病指征的改善情况
- Author:
Xiao Xiao MI
1
;
Jian YAN
1
;
Jun Ping SHI
1
Author Information
1. Centre for Translational Medicine, Hangzhou Normal University Affiliated Hospital, Hangzhou 310015, China.
- Publication Type:Journal Article
- Keywords:
Disease;
Indications;
Non-alcoholic fatty liver disease;
Zebrafish
- MeSH:
Animals;
Body Weight;
Diet, High-Fat;
Lipids;
Liver/pathology*;
Non-alcoholic Fatty Liver Disease/pathology*;
Triglycerides/metabolism*;
Zebrafish/metabolism*;
Zebrafish Proteins
- From:
Chinese Journal of Hepatology
2023;31(7):742-749
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To detect the therapeutic efficacy of FGF21 analogues on the zebrafish model of non-alcoholic fatty liver disease. Methods: A zebrafish model of non-alcoholic fatty liver disease was established by providing the normal diet fed to wild-type zebrafish three times daily. PF-05231023 was administered exogenously at a final concentration of 0.5 μmol/L. Body length, body weight, triglycerides, and other indexes were measured after 20 days. Pathological changes were evaluated in liver tissue sections by HE staining. Quantitative PCR was used to identify expressional changes in genes related to lipid metabolism, endoplasmic reticulum stress, and inflammation. Results: QPCR and immunofluorescence staining results showed that FGF21 was highly expressed in the zebrafish model group. The addition of the FGF21 analogue PF-05231023 significantly reduced the body length and body weight (P < 0.01), and the triglyceride content (P < 0.05) in the zebrafish model group. The liver HE staining results showed that PF-05231023 had alleviated the large and tiny bullae fat, lesions, and others in the zebrafish model group. The quantitative PCR results demonstrated that PF-05231023 reduced the expression of lipogenic factors (P < 0.01), inflammatory-related factors (P < 0.001), and genes related to endoplasmic reticulum stress (P < 0.05), but raised lipid-oxidation-related factors (P < 0.05) in the zebrafish model group. The addition of PF-05231023 reduced oleic acid-induced lipid and triglyceride levels in HepG2 cells. Conclusion: FGF21 analogue addition can improve indexes in the zebrafish disease model of non-alcoholic fatty liver disease.
